Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 14, 2022

Overall Survival With First-Line Atezolizumab Plus Vemurafenib and Cobimetinib in BRAFV600-Positive Advanced Melanoma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Lancet Oncol 2022 Nov 29;[EPub Ahead of Print], PA Ascierto, D Stroyakovskiy, H Gogas, C Robert, K Lewis, S Protsenko, RP Pereira, T Eigentler, P Rutkowski, L Demidov, N Zhukova, J Schachter, Y Yan, I Caro, C Hertig, C Xue, L Kusters, GA McArthur, R Gutzmer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading